Local ablative radiotherapy for oligometastatic non-small cell lung cancer
Radiation Oncology Journal. 2019;37(3):149-155 
The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer
Lung Cancer. 2016;92:22-28
Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer
Clinical Lung Cancer. 2017;18(6):595-606
SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer (NSCLC): a randomised phase III trial
Lung Cancer. 2020;139:S91
119: SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer (NSCLC). A UK randomised phase III trial
Lung Cancer. 2017;103:S54
The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms
Cancer Research and Treatment. 2011;43(2):75-82
154 Radiotherapy for non-small cell lung cancer: From 3D conformal to 4D to stereotactic ablative radiotherapy (SABR) in a year – the Birmingham experience
Lung Cancer. 2013;79:S52
Challenges in the Treatment of Oligometastatic Non-small Cell Lung Cancer
Lung Cancer - Modern Multidisciplinary Management. 2021;
138 Stage I non small cell lung cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative radiotherapy
Lung Cancer. 2016;91:S50
Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer (NSCLC): analysis of T3N0M0 patients
Lung Cancer. 2020;139:S31